Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | KDM4A | O75164 | 2/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 0.75 |
| ▸ | KDM6A | O15550 | 1/20 | 0.75 |
| ▸ | TET3 | O43151 | 1/20 | 0.75 |
| ▸ | KDM4B | O94953 | 1/20 | 0.75 |
| ▸ | KDM5C | P41229 | 1/20 | 0.75 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.75 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.75 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.75 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.75 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.75 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.75 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.75 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.75 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068195 | 0.86 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL29349767 | 0.86 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL69905 | 0.85 | KDM4E (0.74) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL11159839 | 0.84 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL8617622 | 0.83 | KDM4E (0.71) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL23754362 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7373143 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL5761539 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL15129840 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL4519716 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114534694-B | Hydroxyquinoline filler and preparation method and application thereof | 万华化学集团股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-117567994-A | Low-conductivity antifreezing cooling liquid and preparation method thereof | 道骐科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114534694-A | Hydroxyquinoline filler and preparation method and application thereof | 万华化学集团股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | claimed |
| CN-114534694-B | Hydroxyquinoline filler and preparation method and application thereof | 万华化学集团股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117567994-A | Low-conductivity antifreezing cooling liquid and preparation method thereof | 道骐科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023247488-A1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| CN-114534694-A | Hydroxyquinoline filler and preparation method and application thereof | 万华化学集团股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-1829712-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| EP-1651640-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009994-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | KDM4E 1010/4885L3MBTL1 4649/4885KDM4A 506/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | KDM4E 3109/4885L3MBTL1 4529/4885KDM4A 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.